Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Frewer

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
The New England Journal of Medicine|April 30, 2015
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerPasi A Jänne, James Chih-Hsin Yang, Dong-Wan Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I StudyTimothy A Yap, Matthew G Krebs, Sophie Postel-Vinay, et al.
Cancer Discovery|October 20, 2022
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTONRyan J Hartmaier, Aleksandra A Markovets, Myung Ju Ahn, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
The New England Journal of Medicine|April 30, 2015
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerPasi A Jänne, James Chih-Hsin Yang, Dong-Wan Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I StudyTimothy A Yap, Matthew G Krebs, Sophie Postel-Vinay, et al.
Cancer Discovery|October 20, 2022
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTONRyan J Hartmaier, Aleksandra A Markovets, Myung Ju Ahn, et al.
Pageof 2